Get the Stockscreener App
4.92
1.20%
-0.06
After Hours:
4.97
0.05
+1.02%
Nextcure Inc stock is traded at $4.92, with a volume of 33,615.
It is down -1.20% in the last 24 hours and up +946.81% over the past month.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
See More
Previous Close:
$4.98
Open:
$4.99
24h Volume:
33,615
Relative Volume:
0.16
Market Cap:
$11.13M
Revenue:
-
Net Income/Loss:
$-58.52M
P/E Ratio:
-2.3541
EPS:
-2.09
Net Cash Flow:
$-45.03M
1W Performance:
+3.36%
1M Performance:
+946.81%
6M Performance:
+517.70%
1Y Performance:
+201.84%
1-Day Range:
$4.92
$5.2265
1-Week Range:
$4.78
$5.37
52-Week Range:
$0.224
$5.37
Nextcure Inc Stock (NXTC) Company Profile
Name
Nextcure Inc
Sector
Industry
Phone
240-399-4900
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
4.92 | 11.13M | 0 | -58.52M | -45.03M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| Mar-05-21 | Upgrade | Truist | Hold → Buy |
| Jan-15-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-16-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-13-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-13-20 | Downgrade | SunTrust | Buy → Hold |
| Jun-01-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-01-20 | Downgrade | The Benchmark Company | Buy → Hold |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Mar-24-20 | Initiated | The Benchmark Company | Buy |
| Mar-02-20 | Initiated | ROTH Capital | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-05-19 | Initiated | Needham | Buy |
| Nov-26-19 | Initiated | BTIG Research | Buy |
| Jul-09-19 | Initiated | BofA/Merrill | Buy |
| Jun-03-19 | Initiated | Morgan Stanley | Overweight |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Nextcure Inc Stock (NXTC) Latest News
NextCure Inc. Stock Analysis and ForecastBreakthrough financial growth - jammulinksnews.com
What drives NextCure Inc. stock priceExceptional return forecasts - jammulinksnews.com
What analysts say about NextCure Inc. stockExceptional market performance - jammulinksnews.com
Is NextCure Inc. a good long term investmentHigh-octane financial growth - Autocar Professional
What makes NextCure Inc. stock price move sharplyConsistent Growth Alert - Newser
Why NextCure Inc. stock attracts strong analyst attentionFree Access to Community - Newser
How NextCure Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser
Piper Sandler lowers NextCure stock price target to $15 after reverse split By Investing.com - Investing.com South Africa
Piper Sandler lowers NextCure stock price target to $15 after reverse split - Investing.com India
NextCure initiates one-for-twelve reverse stock split on Nasdaq By Investing.com - Investing.com Nigeria
NextCure Implements Reverse Stock Split on Nasdaq - TipRanks
NextCure initiates one-for-twelve reverse stock split on Nasdaq - Investing.com
NextCure Announces One-for-Twelve Reverse Stock Split - TipRanks
NextCure announces 1-for-12 reverse stock split effective July 14 - Investing.com Nigeria
NextCure announces 1-for-12 reverse stock split effective July 14 By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
NextCure’s (NXTC) Buy Rating Reaffirmed at HC Wainwright - Defense World
Eyes on Asia: AstraZeneca, NextCure, Sagimet Biosciences - BioXconomy
Nextcure Inc: Analyzing NXTC Stock Trends - investchronicle.com
Market Recap: Next Technology Holding Inc (NXTT)’s Positive Momentum, Closing at 1.40 - DWinneX
Market Highlights: Nextcure Inc (NXTC) Ends on a Low Note at 0.50 - DWinneX
NextCure tanks as it teams up with Simcere on novel ADC - The Pharma Letter
NextCure and Simcere partner to develop SIM0505 for solid tumours - Yahoo Home
NextCure partners with Simcere Zaiming on cancer drug development By Investing.com - Investing.com South Africa
NextCure Joins China-ADC Gold Rush with $745M Simcere Deal - BioSpace
NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline - Asianet Newsable
NextCure And Simcere Zaiming Partner To Develop CDH6-Targeting ADC SIM0505 For Solid Tumors - Nasdaq
NextCure signs up to $745 million deal with China's Simcere to develop cancer drug - MarketScreener
Simcere Pharmaceutical's Unit Enters Into License Agreement With Nextcure - marketscreener.com
NextCure Enters Licensing Agreement with Simcere Zaiming - TipRanks
NextCure (NXTC) Partners with Simcere Zaiming for Innovative Cancer Treatment | NXTC Stock News - GuruFocus
NextCure partners with Simcere Zaiming on cancer drug development - Investing.com Australia
Nextcure And Simcere Zaiming Announce Strategic Partnership For A Novel Antibody-Drug Conjugate Targeting CDH6 - marketscreener.com
Simcere Enters Strategic License Agreement with NextCure for Oncology Advancements - TipRanks
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 - GlobeNewswire
NextCure Lands Massive $745M Deal for Revolutionary Cancer Drug: Phase 1 Trials Starting Q3 2025 - Stock Titan
Nextcure Inc Stock (NXTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):